DONATE

Market-driven technology transfer

IBEC is committed to turning research results into practical applications, providing innovative solutions to industry and to hospitals, and, ultimately, to society. We carry out Market-Driven Technology Transfer, managing our … Read more

IBEC’s platforms recognised in new ICTS map of cutting-edge research services in Spain

IBEC’s Core Facilities have been included in MINECO’s updated ICTS (Infraestructuras Científicas y Técnicas Singulares) map as part of NANBIOSIS, an integrated platform for research-oriented medical applications.

Created by combining the service platforms within the CIBER-BBN and CCMIJU (the Center for Minimally Invasive Surgery Jesus Uson), NANBIOSIS (Infraestructuras Integrada de Producción y Caracterización de Nanomateriales, Biomateriales y Sistemas en Biomedicina) aims to be a ‘one-stop-shop’ service facility for the design and production of biomaterials and nanomaterials, among other applications.

“Investing in the future”

Josep A. Planell, rector of the UOC and Research Fellow at IBEC, appears in a new documentary about technology transfer in Catalonia, Inversió de Futur.

Presented by Pere Estupinyà, the hour-long documentary, made in by Televisió de Catalunya in collaboration with the CERCA centers, also features other notable names in the Catalan research arena, such as Hble. Sr. Andreu Mas-Colell and director of the PCB Montserrat Vendrell.

Presenting IBEC projects and Core Facilities at major chemistry show

IBEC is participating this week in Expoquimia, the international chemistry trade show whose 17th edition is taking place from 30 September to 3 October at the Fira Gran Via in Barcelona.

Expoquimia is attended by the leading companies and organizations in the international chemical industry such as BASF, BAYER, Dow Chemical, ICL, REPSOL and SOLVAY. The Fira’s three halls open their doors at 10am today, kicking off a program of workshops, seminars and conferences, as well as the trade exhibition.

IBEC internal collaboration succeeds in measuring bacterial cell response to electrical fields

Two groups working together at IBEC demonstrate the potential of electrical studies of single bacterial cells in a paper published in ACS Nano.

Gabriel Gomila’s Nanoscale Bioelectrical Characterization group and that of Antonio Juárez, Microbial Biotechnology and Host-pathogen Interaction, combined their expertise on microscopic electrical measurements and bacteria respectively to come up with a way to study the response to external electrical fields of just a single bacterial cell.

Scientists develop first light-operated drug for most common target proteins

Researchers in IBEC’s Nanoprobes and Nanoswitches group and their collaborators have announced the development of the first ever light-controlled therapeutic agent whose effects focus specifically on the largest, most important class of drug target proteins – G protein-coupled receptors.

In the journal Nature Chemical Biology this week, the scientists reveal Alloswitch-1, the latest advance in their research into photoswitchable (or light-operated) drugs. Controlling drug activity with light means that the therapeutic effects can be accurately delivered locally, thus reducing their effect on other areas and the resultant side effects, and helps reduce the dosage required.

In-house equipment

To make in-house reservations, either for the BioSpace lab or for the other equipment, click here: BioSpace Lab The BioSpace Lab is a shared communal space located in the basement … Read more